1-s2.0-S0264410X13000820-main.pdf (475.93 kB)
Monoclonal antibodies for prophylactic and therapeutic use against viral infections
journal contribution
posted on 2023-06-09, 14:32 authored by Leonard Both, Ashley C Banyard, Craig van Dolleweerd, Edward WrightEdward Wright, Julian K C Ma, Anthony R FooksNeutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously target multiple viral epitopes and to overcome issues of neutralization escape. Advances in antibody engineering have led to a large array of novel mAb formats, while deeper insight into the biology of several viruses and increasing knowledge of their neutralizing epitopes has extended the list of potential targets. In addition, progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable.
History
Publication status
- Published
File Version
- Published version
Journal
VaccineISSN
0264410XPublisher
ElsevierExternal DOI
Issue
12Volume
31Page range
1553-1559Department affiliated with
- Biochemistry Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2018-08-14First Open Access (FOA) Date
2018-08-14First Compliant Deposit (FCD) Date
2018-08-14Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC